These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25775905)

  • 21. [Molecular basis of familial hypercholesterolemia-like phenotype heterogeneity].
    Wang LY; Lin J; Liu S; Chen BS
    Yi Chuan Xue Bao; 2005 Jul; 32(7):770-7. PubMed ID: 16078748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
    Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
    Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects.
    Jannes CE; Santos RD; de Souza Silva PR; Turolla L; Gagliardi AC; Marsiglia JD; Chacra AP; Miname MH; Rocha VZ; Filho WS; Krieger JE; Pereira AC
    Atherosclerosis; 2015 Jan; 238(1):101-7. PubMed ID: 25461735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
    Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
    Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia.
    Zakharova FM; Damgaard D; Mandelshtam MY; Golubkov VI; Nissen PH; Nilsen GG; Stenderup A; Lipovetsky BM; Konstantinov VO; Denisenko AD; Vasilyev VB; Faergeman O
    BMC Med Genet; 2005 Feb; 6():6. PubMed ID: 15701167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JCL Roundtable: diagnosis of severe familial hypercholesterolemia.
    Brown WV; Rader DJ; Kane J
    J Clin Lipidol; 2013; 7(6):540-5. PubMed ID: 24314353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
    Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
    Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.
    Fouchier SW; Dallinga-Thie GM; Meijers JC; Zelcer N; Kastelein JJ; Defesche JC; Hovingh GK
    Circ Res; 2014 Aug; 115(6):552-5. PubMed ID: 25035151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New mutations in low-density lipoprotein receptor gene in familial hypercholesterolemia patients from Petrozavodsk].
    Komarova TY; Golovina AS; Grudinina NA; Zakharova FM; Korneva VA; Lipovetsky BM; Serebrenitskaya MP; Konstantinov VO; Vasilyev VB; Mandelshtam MY
    Genetika; 2013 Jun; 49(6):773-7. PubMed ID: 24450200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Array-based resequencing for mutations causing familial hypercholesterolemia.
    Chiou KR; Charng MJ; Chang HM
    Atherosclerosis; 2011 Jun; 216(2):383-9. PubMed ID: 21376320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
    Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
    J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe.
    Stef MA; Palacios L; Olano-Martín E; Foe-A-Man C; van de Kerkhof L; Klaaijsen LN; Molano A; Schuurman EJ; Tejedor D; Defesche JC
    J Mol Diagn; 2013 May; 15(3):362-72. PubMed ID: 23537714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
    Saavedra YGL; Dufour R; Baass A
    J Clin Lipidol; 2015; 9(6):786-793.e1. PubMed ID: 26687699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia.
    Taylor A; Tabrah S; Wang D; Sozen M; Duxbury N; Whittall R; Humphries SE; Norbury G
    Clin Genet; 2007 Jun; 71(6):561-8. PubMed ID: 17539906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
    Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.